The trial will be testing if it “works “ . A clear Response &...

The trial will be testing if it “works “ .
A clear Response & Remission of the actual (breast , ovarian etc also ) cancer cells .
The following -on AML R/R trial just adds to great amount of previous work, .. done better and seeking greater effectiveness again now .
MRD +ve is where bisantrene can really make a difference though to save lives & give patients their best survival chances before their marrow transplant if possible. This is incredibly exciting - wonderful to get bisantrene into the oncology armamentarium.
We are told the IND is now well- progressed . (for the FDA - and US trials base )

All evidence already says ~ Yes bisantrene will work , this is actually known .

It’s the dosages as well ( also really known or can be determined now ) ; & the combinations that will be tested for efficacy & real effectiveness and of course safety .
But any combination treatment with Bisantrene will already be with extensively prior tested agents & testing together and with knowledge of & targeting synergies — *always with the aim for best specificity against the patients cancer. *
This is what it’s about. Treatment is very much lead by real knowledge of likely effectiveness as I’m sure you also realise .
Importantly - Not in question : Safety and ethics, & that is real needed benefit to be gained treating cancers where nothing else is as effective and where these patients will die with only the existing standard care to hand - as likelihood, and new oncology treatments are needed . Bisantrene really has a place here .

It is not an experiment or about applying logic.
Cannot be like this in medical research. Must be evidence based , beyond safety and effectiveness and efficacy proving extensively- before ever goes into forming a broad treatment phase trial .

The FTO protein targeting by bisantrene is pivotal and seems also to be Fact . Now that it is known that this is a likelihood for ‘why’ bisantrene has always been additionally more effective against many difficult to treat cancers , where the standard anthracyclines have not succeeded in fully eliminating the cancer - including breast cancer , ovarian , bladder , ‘progressed ‘ , refractory AML , even brain / liver cancers/ kidney cancers